Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mina Sooch
Observed names:
MINA SOOCH,
Mina P Sooch,
Mina P. Sooch,
Mina Patel Sooch
Institution:
Ocuphire Pharma (United States)
Observed institutions:
Ocuphire Pharma (United States),
ProNAi Therapeutics (United States),
NeuroBo Pharmaceuticals, Inc. (United States)
OpenAlex ID:
A5020200197
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors
2013
·
Anthony W. Tolcher
, Wendi V. Rodrigueza
, et al.
·
Cancer Chemotherapy and Pharmacology
·
90
PDF
Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide
2014
·
Wendi V. Rodrigueza
, Michael J. Woolliscroft
, et al.
·
Cancer Chemotherapy and Pharmacology
·
29
PDF
The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma
2014
·
Wael A. Harb
, Nehal Lakhani
, et al.
·
Blood
·
14
Phentolamine Mesylate Ophthalmic Solution Provides Lasting Pupil Modulation and Improves Near Visual Acuity in Presbyopic Glaucoma Patients in a Randomized Phase 2b Clinical Trial
2021
·
Jay S Pepose
, Paul J Hartman
, et al.
·
Clinical ophthalmology
·
12
PDF
A randomized phase 2 clinical trial of phentolamine mesylate eye drops in patients with severe night vision disturbances
2022
·
Jay Pepose
, Mitchell Brigell
, et al.
·
BMC Ophthalmology
·
6
PDF
Phentolamine Eye Drops Reverse Pharmacologically Induced Mydriasis in a Randomized Phase 2b Trial
2021
·
Paul M. Karpecki
, Shane A. Foster
, et al.
·
Optometry and Vision Science
·
5
Reversal of Pharmacologically Induced Mydriasis with Phentolamine Ophthalmic Solution
2024
·
Jay S. Pepose
, David Wirta
, et al.
·
Ophthalmology
·
4
PDF
The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active In Patients With Relapsed Or Refractory Non-Hodgkin’s Lymphoma
2013
·
Wael A. Harb
, Nehal Lakhani
, et al.
·
Blood
·
4
25-LB: Oral APX3330 Reduces the DRSS Worsening after 24-weeks of Daily Treatment—Efficacy and Safety Results of the ZETA-1 Phase 2 Trial in Diabetic Retinopathy
2023
·
VICTOR H. GONZALEZ
, MITCHELL G. BRIGELL
, et al.
·
Diabetes
·
3
Phentolamine mesylate ophthalmic solution provides long lasting pupil modulation and improves visual acuity
2020
·
Jay S. Pepose
, Bill Pitlick
, et al.
·
Investigative Ophthalmology & Visual Science
·
1
Pharmacokinetics of the BCL2-targeted DNA interference (DNAi) nanoparticle PNT2258 in patients with recurrent or refractory non-Hodgkin lymphoma.
2014
·
Wael Harb
, Nehal J. Lakhani
, et al.
·
Journal of Clinical Oncology
·
1
Lynx-1: Phentolamine Ophthalmic Solution For Dim Light Vision Disturbance
2023
·
Mina Sooch
, Obaidah Bitar
, et al.
·
ESCRS Abstracts
Oral Apx3330 Reduces The Drss Worsening After 24-Weeks Of Daily Treatment: Efficacy And Safety Results Of The Zeta-1 Phase 2 Trial In Diabetic Retinopathy
2023
·
Mina Sooch
, Louis Haddad
, et al.
·
ESCRS Abstracts
Treatment With 0.75% Phentolamine Ophthalmic Solution Reverses Mydriasis In Healthy Subjects: Results From Mira-2 And Mira-3, Pivotal Phase 3 Clinical Trials
2023
·
Mitchell Jackson
, Mina Sooch
, et al.
·
ESCRS Abstracts
Vega-1: A Phase 3, Double-Masked, Randomized, Placebo-Controlled Study Of Pos And Ldp In Presbyopic Patients
2023
·
Mina Sooch
, Louis Haddad
, et al.
·
ESCRS Abstracts
Phentolamine mesylate ophthalmic solution reduces time to recovery of medically-induced mydriasis in a Phase 2 trial
2020
·
Paul Karpecki
, Bill Pitlick
, et al.
·
Investigative Ophthalmology & Visual Science
Abstract 13654: Gemcabene Monotherapy and in Combination With Atorvastatin Lowers High Sensitivity C-Reactive Protein (hsCRP) in a Phase 2 Clinical Trial
2015
·
Evan A Stein
, Rebecca Bakker-Arkenma
, et al.
·
Circulation
Abstract 5473: The sensitivity of targeting genomic BCL2 by PNT2258 is linked to chromosomal rearrangements and proliferative rate of tumor types
2014
·
Michael J. Woolliscroft
, Abdul-Shukkur Ebrahim
, et al.
·
Cancer Research
Show more works
View as search
Works count:
18
Citation count:
169
H-index:
5
I10-index:
4
Year
Topic
Type